创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Key Features of MHC Humanized Mouse Models

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-28 09:58
  • Views:

(Summary description)With the rapid development of biotechnology, mankind's understanding of diseases and means of treatment continue to progress. As a major innovation in the field of biomedical research, the InnoModels Biotechnology MHC humanized mouse model is gradually unraveling the mystery of complex diseases and injecting new vitality into medical progress.

InnoModels Biotechnology: Key Features of MHC Humanized Mouse Models

(Summary description)With the rapid development of biotechnology, mankind's understanding of diseases and means of treatment continue to progress. As a major innovation in the field of biomedical research, the InnoModels Biotechnology MHC humanized mouse model is gradually unraveling the mystery of complex diseases and injecting new vitality into medical progress.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-28 09:58
  • Views:
Information

With the rapid development of biotechnology, mankind's understanding of diseases and means of treatment continue to progress. As a major innovation in the field of biomedical research, the InnoModels Biotechnology MHC humanized mouse model is gradually unraveling the mystery of complex diseases and injecting new vitality into medical progress.
MHC, or major histocompatibility complex, is the key to the human immune system's ability to recognize "self" and "not-self". InnoModels has successfully implanted the human MHC gene into mice, creating a humanized mouse model of MHC. This mouse model not only has the ability to highly mimic the human immune system, but also has physiological functions and disease responses that are closer to those of humans, providing a more accurate tool for disease research.

 


The main features of the MHC humanized mouse model are:
1. Highly mimic the human immune system: Through gene editing technology, the MHC genes of mice are replaced with human MHC genes, enabling their immune systems to more realistically mimic human immune responses. This is of great significance for the study of autoimmune diseases, infectious diseases and tumor immunity.
2. Predictability of disease models: Since the immune system of mice is closer to that of human beings, the disease models established using MHC humanized mouse models are more predictable. This is important for drug development and clinical trial design.
3. Improvement of drug development efficiency: Using MHC humanized mouse models for drug screening and effect evaluation can more accurately predict drug responses in the human body, thus shortening the drug development cycle and improving R&D efficiency.
4. Potential for personalized medicine: The MHC humanized mouse model can also be used to simulate the differences in immune responses of different individuals, providing the possibility of personalized medicine. Through the analysis of the model, it can be used to more accurately predict an individual's response to the drug and the therapeutic effect.
In conclusion, the successful creation of the InnoModels Biotechnology MHC humanized mouse model not only provides a powerful tool for biomedical research, but also offers new ideas and methods for drug development and clinical treatment. In the future, with the continuous improvement and optimization of this technology, we have reason to believe that it will contribute more to human health and medical progress.    

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司